Gain Therapeutics, Inc. filings document a clinical-stage biotechnology issuer with Nasdaq-listed common stock and emerging growth company status. Recent Form 8-K disclosures cover financial results, business updates, Regulation FD materials, scientific presentations, and clinical or biomarker updates related to GT-02287 and Parkinson’s disease.
The company’s proxy materials describe annual meeting matters, director elections, board composition, executive compensation, equity awards and auditor ratification. Other filings record governance changes, including board membership updates, and identify the company’s registered common stock, Delaware incorporation and reporting framework.
Gain Therapeutics reported preliminary results from its ongoing Phase 1b study of GT-02287 in people with Parkinson’s disease, with or without a GBA1 mutation. After 90 days of dosing, GT-02287 has been safe and generally well tolerated, with no treatment-emergent serious adverse events. Some participants showed transient increases in alkaline phosphatase and other liver enzymes, which returned to normal even while treatment continued.
The 21 participants include treatment-naïve patients, individuals on deep brain stimulation, and most on levodopa and other Parkinson’s drugs. Several participants experienced improvements in their MDS-UPDRS Part II and III scores by Day 90, while mean Part I scores were unchanged. The company notes that the mean improvement in Parts II and III by Day 90, not seen by Day 30, suggests a potential disease-slowing effect consistent with preclinical models and the proposed mechanism of GT-02287. Plasma pharmacokinetics were consistent across sampled participants and within the projected therapeutic range.
A data monitoring committee has twice recommended continuing the study, and Australian health authorities have approved an extension allowing patients to be treated for up to 12 months.
Gain Therapeutics reported operating losses and tightened liquidity in the first half of 2025 while continuing clinical development of its lead program. For the six months ended June 30, 2025 the company recorded a $10.34 million net loss, with total operating expenses of $9.46 million. Cash and cash equivalents were $6.69 million at June 30, 2025, down from $10.39 million at year-end 2024, and total assets were $9.83 million versus total liabilities of $6.14 million, leaving stockholders' equity of $3.70 million.
The company disclosed a going concern assessment, stating its June 30, 2025 cash is insufficient to fund operations for 12 months and that it will need additional capital to continue beyond Q1 2026. Management noted recent financings including ATM sales and a July 2025 public offering that generated net proceeds (July offering net proceeds of $6.1 million plus an additional $1.0 million from over-allotment) and described actions to optimize costs and pursue collaborations. The lead clinical candidate GT-02287 completed a Phase 1 study (n=72) that was reported as safe and generally well tolerated, supporting further development.
Gain Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025 and provided a business update; that press release is included as Exhibit 99.1 to this Current Report. The filing also references an Interactive Data File as Exhibit 104.
The registrant indicates it is an emerging growth company and its common stock trades under GANX on The NASDAQ Stock Market. The company states the press release and related information are furnished and therefore are not deemed filed for purposes of Section 18 of the Exchange Act and are not incorporated by reference into other filings except by specific reference. This 8-K does not include the financial statements or numeric results within its text.
Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing the award of a stock option to director Khalid Islam on 06/24/2025. The option covers 15,000 shares of common stock at an exercise price of $1.79 per share and expires on 06/24/2035. According to the filing, the grant will vest in 12 equal monthly installments beginning 07/24/2025, contingent upon Mr. Islam’s continued service with the company. Following the grant, Mr. Islam beneficially owns 15,000 derivative securities directly. No non-derivative share transactions were reported.
The filing is routine and reflects a standard equity-based compensation mechanism used to align director incentives with shareholder interests. No changes to ownership structure, sales of shares, or additional material financial data were included.
Key take-away: On 06/24/2025 Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Claude Nicaise received a stock option covering 15,000 shares of common stock at an exercise price of $1.79 per share, expiring on 06/24/2035.
The option was awarded, not exercised, and therefore does not immediately affect the public float. Vesting occurs in 12 equal monthly tranches starting 07/24/2025, contingent on Mr. Nicaise’s continued service. After the grant, the director directly holds 15,000 derivative securities; no non-derivative holdings or sales were reported.
This represents routine equity compensation aimed at further aligning board incentives with shareholder interests. No cash changed hands and no other material transactions were disclosed in this filing.
Key take-away: Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Jeffrey Scott Riley received a grant of 15,000 stock options on 06/24/2025.
The option has an exercise price of $1.79 per share and expires on 06/24/2035. The transaction is coded “A” (acquisition) and represents the only derivative security currently reported for the director; no common shares were bought or sold.
Vesting schedule: the award vests in 12 equal monthly installments beginning 07/24/2025, provided Mr. Riley continues his service. Following the grant he beneficially owns 15,000 options, classified as direct ownership. No indirect holdings or Rule 10b5-1 trading plan were indicated.
Investor relevance: This filing reflects standard director compensation and does not involve open-market buying or selling. While the grant modestly increases potential future dilution, its size is immaterial relative to GANX’s total shares outstanding. The filing may signal management’s effort to align director incentives with shareholder value but is unlikely to move the stock on its own.
Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing a routine equity award to director Eric I. Richman. On 06/24/2025 the director received 15,000 stock options with an exercise price of $1.79 per share.
The options vest in 12 equal monthly installments beginning 07/24/2025, contingent on continued board service, and expire on 06/24/2035. Following the grant, Richman beneficially owns 15,000 derivative securities, all held directly. No shares of common stock were bought or sold, and no other transactions were reported.
Gain Therapeutics, Inc. (GANX) filed a Form 4 disclosing that director Hans Peter Hasler received 15,000 stock options on 06/24/2025. The options carry a $1.79 exercise price, expire on 06/24/2035, and will vest in 12 equal monthly tranches beginning 07/24/2025, contingent on continued board service. No common shares were bought or sold; the filing solely reflects an equity-incentive grant. After the transaction, Hasler beneficially owns 15,000 derivative securities, all held directly. The grant is routine board compensation and does not signal any change in the company’s operating outlook, capital structure, or insider sentiment.